SOPURA acquired by KERSIA
Context
Kersia acquired 100% of Sopura from its shareholders as part of a strategic build-up program. This transaction was integrated into a larger financing package arranged during the acquirer's own ownership transition to a new private equity sponsor. The acquisition represents a major strategic shift, allowing the group to significantly increase its exposure to the beverage industry—moving from less than 2% to over 15% of its pro forma revenue. Strategically, the deal combines the target's specialized brewing hygiene expertise and rinse-free product lines with the acquirer's global food safety platform. Geographically, the operation provides the acquirer with immediate access to established manufacturing sites in Australia, South Africa, and Vietnam, while offering the target's products a pathway into North and South American markets through the group's existing network.
SOPURA, which reported an EBITDA margin of in 2019, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Founded as a specialized chemical and hygiene player, Sopura is a global leader in water treatment and hygiene solutions specifically tailored for the brewing and beverage industries. The company operates a global Corporate footprint with manufacturing facilities in Belgium, Spain, Australia, South Africa, and Vietnam. It is recognized for its high-technical expertise in environmental hygiene and its proprietary portfolio of ecological, rinse-free disinfectant products. By serving major international breweries and beverage producers, the firm has established itself as a critical partner in ensuring food safety and operational efficiency within the liquid food supply chain. Its international presence and specialized product range make it a key contributor to the global beverage industry s hygiene standards.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (EUR)
Similar deals in Healthcare Services
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 10/2023 | MOTION EQUITY PARTNERS | BANOOK | FRANCE | CRO / Clinical Trials |
| 09/2023 | CERBA HEALTHCARE | CIRION BIOPHARMA RESEARCH | CANADA | CRO / Clinical Trials |
| 09/2023 | PERMIRA | ERGOMED | UNITED KINGDOM | CRO / Clinical Trials |
| 06/2023 | SUPERNOVA INVEST / HEAL CAPITAL | GLEAMER | FRANCE | Health Tech |
| 06/2022 | ASTORG | OPEN HEALTH | UNITED STATES | Healthcare Services |
| 10/2020 | IK PARTNERS | KERSIA | FRANCE | Sterilization & Hygiene |
| 05/2020 | CLAYTON, DUBILIER & RICE (CD&R) | HUNTSWORTH | UNITED KINGDOM | Healthcare Services |
| 01/2018 | SPECTRIS | CONCEPT LIFE SCIENCES | UNITED KINGDOM | CRO / Clinical Trials |
| 04/2016 | CHARLES RIVER LABORATORIES | WIL RESEARCH | UNITED STATES | CRO / Clinical Trials |
| 04/2015 | CLINIGEN GROUP | IDIS | UNITED KINGDOM | Healthcare Services |
REFERENCES
Revenue range: 50M - 100M EUR
EBITDA range: 5M - 25M EUR
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of SOPURA by KERSIA are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Acquirer: kersia